Background and purpose: Lymphoma is the most common hematopoietic malignant tumor. B-cell non-Hodgkin’s lymphoma (NHL) accounts for more than 90% of lymphomas. The most common subtype in B-cell NHL is diffuse large B-cell lymphoma (DLBCL). This study aimed to investigate the expression of calreticulin in DLBCL and its clinical significance. Methods: Immunohistochemical staining was used to detect the expres

sion of calreticulin and other proteins in tumor tissues of 143 DLBCL patients treated in Zhongshan Hospital

Fudan University from 2015 to 2018. Association between the expression of calreticulin and the clinicopathologic characteristics and prognosis of DLBCL patients was analysed. Results: Among 143 DLBCL patients

92 were positive for calreticulin

and the positive expression rate was 64.3%. The proportion of death in the calreticulin positive group (26.1%) was significantly higher than that in the calreticulin negative group (9.8%)

and the difference was statistically significant (χ

2

=5.381

P=0.020). Kaplan-Meier survival curve showed that the calreticulin positive group had a shorter survival time than the negative group (χ

2

=5.285

P=0.022). Conclusion: In DLBCL patients

expression level of calreticulin was closely related to prognosis of DLBCL patients. Calreticulin can be used as one of the indicators of clinical prognosis evaluation.